# Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in p...
**Top News**

**2023-10-30 06:21**

**https://www.ainvest.com/news/novartis-investigational-atrasentan-phase-iii-study-demonstrates-clinically-meaningful-and-highly-statistically-significant-proteinuria-reduction-in-patients-with-iga-nephropathy-igan-23101000824fc8b6dd6d08c7/**

Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)